A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC

Stopped The study was terminated as part of the decision by Pfizer to halt its biosimilars programs in China.

Conditions

• Advanced Non-squamous NSCLC

Interventions

• DRUG: PF-06439535 (CN)
• DRUG: Bevacizumab-EU
• DRUG: Paclitaxel
• DRUG: Carboplatin

Sponsor

Pfizer